{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:03:23Z","timestamp":1783191803798,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.7759\/cureus.105756","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:07:18Z","timestamp":1774350438000},"source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease"],"prefix":"10.7759","author":[{"given":"Kohei","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu X","year":"2024","unstructured":"Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024, 20:48-62. 10.1038\/s41584-023-01054-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson SR","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, et al.. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024, 76:1182-200. 10.1002\/art.42861","journal-title":"Arthritis Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji H","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, et al.. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020, 72:488-98. 10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/jmpuxa","article-title":"Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study","volume":"43","author":"You H","year":"2025","unstructured":"You H, Lv C, Xu L, et al.. Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study. Clin Exp Rheumatol. 2025, 43:251-9. 10.55563\/clinexprheumatol\/jmpuxa","journal-title":"Clin Exp Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa K","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, et al.. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018, 57:2114-9. 10.1093\/rheumatology\/key188","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen Z","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019, 381:291-3. 10.1056\/NEJMc1900045","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor PC","year":"2024","unstructured":"Taylor PC, Choy E, Baraliakos X, et al.. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford). 2024, 63:298-308. 10.1093\/rheumatology\/kead448","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu H","year":"2021","unstructured":"Hu H, Yang H, Liu Y, Yan B. Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. Front Med (Lausanne). 2021, 8:833114. 10.3389\/fmed.2021.833114","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658547","article-title":"Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study","volume":"16","author":"Gao C","year":"2025","unstructured":"Gao C, Wei G, Li C, et al.. Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. Front Immunol. 2025, 16:1658547. 10.3389\/fimmu.2025.1658547","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu W","year":"2025","unstructured":"Wu W, Guo B, Sun W, et al.. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. Eur Respir J. 2025, 65:2401488. 10.1183\/13993003.01488-2024","journal-title":"Eur Respir J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan L","year":"2022","unstructured":"Fan L, Lyu W, Liu H, et al.. A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus. J Rheumatol. 2022, 49:1356-64. 10.3899\/jrheum.220367","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03675-9","article-title":"Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease","volume":"27","author":"Zhu S","year":"2025","unstructured":"Zhu S, Li S, Shi L, et al.. Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease. Arthritis Res Ther. 2025, 27:214. 10.1186\/s13075-025-03675-9","journal-title":"Arthritis Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett M","year":"2024","unstructured":"Beckett M, Dutz J, Huang K. Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients. RMD Open. 2024, 10:10.1136\/rmdopen-2023-003837","journal-title":"RMD Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, 76:1955-64. 10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152231","article-title":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review","volume":"62","author":"Xie H","year":"2023","unstructured":"Xie H, Zhang D, Wang Y, et al.. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review. Semin Arthritis Rheum. 2023, 62:152231. 10.1016\/j.semarthrit.2023.152231","journal-title":"Semin Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002770","article-title":"Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study","volume":"9","author":"Abe K","year":"2023","unstructured":"Abe K, Furuta S, Kobayashi Y, et al.. Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study. RMD Open. 2023, 9:10.1136\/rmdopen-2022-002770","journal-title":"RMD Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura SI","year":"2021","unstructured":"Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep. 2021, 5:76-81. 10.1080\/24725625.2020.1816674","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida T","year":"2023","unstructured":"Ida T, Furuta S, Takayama A, et al.. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. 2023, 9:10.1136\/rmdopen-2022-002795","journal-title":"RMD Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002274","article-title":"Prophylaxis with valganciclovir in anti-melanoma differentiation associated 5 gene antibody dermatomyositis: a cohort study in China","volume":"32","author":"Shanshan L","year":"2026","unstructured":"Shanshan L, Xiaoxing W, Ling Z, Jianghui D, Xia L, Lu Z. Prophylaxis with valganciclovir in anti-melanoma differentiation associated 5 gene antibody dermatomyositis: a cohort study in China. J Clin Rheumatol. 2026, 32:21-4. 10.1097\/RHU.0000000000002274","journal-title":"J Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxae082","article-title":"Refractory skin ulcers and afebrile bacteraemia with Staphylococcus aureus in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a case report","volume":"9","author":"Katakura T","year":"2025","unstructured":"Katakura T, Shirai T, Ishii Y, Sato H, Fujii H. Refractory skin ulcers and afebrile bacteraemia with Staphylococcus aureus in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a case report. Mod Rheumatol Case Rep. 2025, 9:rxae082. 10.1093\/mrcr\/rxae082","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u03b3: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies","volume":"22","author":"Thuner J","year":"2023","unstructured":"Thuner J, Coutant F. IFN-\u03b3: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies. Autoimmun Rev. 2023, 22:103420. 10.1016\/j.autrev.2023.103420","journal-title":"Autoimmun Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves PG","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021, 80:865-75. 10.1136\/annrheumdis-2020-219012","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/463801-upadacitinib-for-refractory-anti-melanoma-differentiation-associated-gene-5-antibody-positive-dermatomyositis-related-interstitial-lung-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:07:18Z","timestamp":1774350438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/463801-upadacitinib-for-refractory-anti-melanoma-differentiation-associated-gene-5-antibody-positive-dermatomyositis-related-interstitial-lung-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.105756","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}